In terms of source innovation, universities and research institutes focus on fundamental target discovery, while enterprises lead engineering-based translation and implementation. Effective ...
EDMONTON, ALBERTA, CANADA, February 2, 2026 /EINPresswire.com/ — AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha ...
Under the collaboration, Daiichi Sankyo will work with Leveragen to apply Leveragen’s in vivo antibody discovery capabilities in support of selected research programs. The collaboration reflects a ...
AdvanCell and 48Hour Discovery Announce Collaboration and Exclusive Licensing Agreement to Develop a Lead-212 Alpha Radioligand Therapy Program EDMONTON, ALBERTA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results